← Back to Screener
Precision BioSciences, Inc. Common Stock (DTIL)
Price$7.02
Value ScoreC
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)24.03%
Price vs S&P 500 (4W)-9.23%
VGM Score62.29
Market Capitalization$179.84M
P/E Ratio (Annual)19.04x
All Metrics
Book Value / Share (Quarterly)$2.95
P/TBV (Annual)1.10x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.93%
Cash Flow / Share (Quarterly)$-2.30
Price vs S&P 500 (YTD)56.61%
Net Profit Margin (TTM)-96.73%
EPS (TTM)$-3.67
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$-3.67
Revenue Growth (5Y)7.13%
EPS (Annual)$-3.56
ROI (Annual)-39.88%
Net Profit Margin (5Y Avg)-144.03%
Cash / Share (Quarterly)$3.92
Revenue Growth QoQ (YoY)37272.41%
P/E Normalized (Annual)19.04x
ROA (Last FY)-29.61%
Revenue Growth TTM (YoY)-11.87%
EBITD / Share (TTM)$-2.27
ROE (5Y Avg)-116.05%
Operating Margin (TTM)-86.85%
Cash Flow / Share (Annual)$-2.76
P/B Ratio2.36x
P/B Ratio (Quarterly)1.86x
Net Income / Employee (Annual)$-672,400
EV / Revenue (TTM)2.28x
Net Interest Coverage (TTM)-8.08x
ROA (TTM)-34.83%
EV / EBITDA (TTM)19.13x
EPS Incl Extra (Annual)$-3.56
Current Ratio (Annual)13.32x
Quick Ratio (Quarterly)13.56x
3-Month Avg Trading Volume0.27M
52-Week Price Return41.67%
Revenue / Employee (TTM)$662,800
Tangible BV / Share (Quarterly)$2.91
P/S Ratio (Annual)5.25x
Asset Turnover (Annual)0.22x
52-Week High$8.82
Operating Margin (5Y Avg)-120.10%
EPS Excl Extra (Annual)$-3.56
CapEx CAGR (5Y)-32.60%
Tangible BV CAGR (5Y)16.17%
26-Week Price Return39.96%
Quick Ratio (Annual)12.97x
13-Week Price Return74.69%
Total Debt / Equity (Annual)0.24x
Current Ratio (Quarterly)14.02x
Enterprise Value$102.89M
Revenue / Share Growth (5Y)-28.21%
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-31.45%
Revenue / Employee (Annual)$503,900
Pretax Margin (Annual)-136.03%
Cash / Share (Annual)$4.80
3-Month Return Std Dev80.59%
Net Income / Employee (TTM)$-641,200
ROE (Last FY)-49.57%
Net Interest Coverage (Annual)-1.31x
EPS Basic Excl Extra (Annual)$-3.56
Receivables Turnover (TTM)22.51x
Total Debt / Equity (Quarterly)0.29x
EPS Incl Extra (TTM)$-3.67
Receivables Turnover (Annual)40.36x
ROI (TTM)-56.52%
P/S Ratio (TTM)3.99x
Pretax Margin (5Y Avg)-105.97%
Revenue / Share (Annual)$2.67
Tangible BV / Share (Annual)$3.78
Price vs S&P 500 (52W)13.46%
Year-to-Date Return67.55%
5-Day Price Return-3.60%
EPS Normalized (Annual)$-3.56
ROA (5Y Avg)-24.82%
Net Profit Margin (Annual)-133.45%
Month-to-Date Return-2.52%
Cash Flow / Share (TTM)$-0.62
EBITD / Share (Annual)$-3.95
Operating Margin (Annual)-152.30%
LT Debt / Equity (Annual)0.24x
ROI (5Y Avg)-69.42%
LT Debt / Equity (Quarterly)0.29x
EPS Basic Excl Extra (TTM)$-3.67
P/TBV (Quarterly)1.89x
P/B Ratio (Annual)1.09x
Pretax Margin (TTM)-98.70%
Book Value / Share (Annual)$3.83
Price vs S&P 500 (13W)64.94%
Beta1.33x
P/FCF (Annual)1.99x
Revenue / Share (TTM)$1.83
ROE (TTM)-79.62%
52-Week Low$3.53
vGradeC
gGradeC
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.75est. -0.67
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.30
4.30
4.30
4.30
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DTILPrecision BioSciences, Inc. Common Stock | C | C | B | $7.02 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Precision BioSciences develops genome editing therapeutics based on its proprietary ARCUS platform. The platform's compact size enables efficient delivery to a wider range of cells and tissues using both viral and non-viral methods, potentially providing competitive advantages. The company applies ARCUS to create product candidates for human disease treatment and agricultural applications.